ANVS Stock Analysis: Buy, Sell, or Hold?
ANVS - Annovis Bio, Inc.
$1.97
0.04 (2.07%)
▲
5d:
+14.53%
30d:
+6.49%
90d:
-13.6%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When ANVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ANVS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ANVS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ANVS is currently trading at $1.97, which is considered extended relative to its 30-day fair value range of $1.73 to $1.91.
Technical Outlook: Technically, ANVS is in a strong downtrend. The price is approaching resistance at $2.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ANVS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.50 (+547.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ANVS is in a strong downtrend. The price is approaching resistance at $2.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ANVS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.50 (+547.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.73 -
$1.91
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 547.7% below Wall St target ($12.50)
Trading Range Analysis
30-Day Trading Range
$1.73 -
$1.91
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.55
(28.1%)
Support & Resistance Levels
Support Level
$1.65
Resistance Level
$2.02
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.66
Wall Street Target
$12.50
(+547.7%)
Share & Embed Analysis
Last updated: July 06, 2026 11:26 AM ET
Data refreshes hourly during market hours. Next update: 12:26 PM
Data refreshes hourly during market hours. Next update: 12:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANVS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Michael B Hoffman
BUY
713800 shares
2026-04-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
